St. Jude proceeds with first U.S. trial of hypertension device

06/7/2013 | MassDevice.com (Boston)

The FDA has granted St. Jude Medical an investigational device exemption to conduct the first U.S. clinical study of its EnligHTN multielectrode device, which uses radiofrequency energy to disrupt the renal nerves believed to control blood pressure. The trial will involve about 590 patients with drug-resistant hypertension.

View Full Article in:

MassDevice.com (Boston)

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Counsel – Regulatory Affairs
RAI Services Company
Winston Salem, NC
Director of Program Development
AdvaMed
Washington DC, DC
Director of System QA
LifeWatch Services, Inc.
Rosemont, IL
Director of Business Development and Membership
AdvaMed
Washington DC, DC
Director, Corporate Counsel
Regeneron
Tarrytown, NY